Literature DB >> 30224535

Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program.

Helio S Sader1, Robert K Flamm2, Cecilia G Carvalhaes2, Mariana Castanheira2.   

Abstract

Pseudomonas aeruginosa isolates (n = 1,909) were collected from 70 U.S. medical centers, and their susceptibilities were tested using the broth microdilution method. Ceftazidime-avibactam (MIC50/MIC90, 2/8 mg/liter) and ceftolozane-tazobactam (MIC50/MIC90, 0.5/2 mg/liter) were the most active (i.e., had the highest susceptibility rates) compounds after colistin, with national susceptibility rates of 96.9% and 97.5%, respectively. Overall, piperacillin-tazobactam (MIC50/MIC90, 4/128 mg/liter) and meropenem (MIC50/MIC90, 0.5/16 mg/liter) were active against 77.5% and 76.0% of the isolates, respectively. Susceptibility variations across census divisions were documented for many antimicrobials.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosazzm321990; antimicrobial resistance; inhibitor combinations; β-lactamases

Mesh：

Substances：

Year:  2018        PMID： 30224535      PMCID： PMC6256773          DOI： 10.1128/AAC.01587-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.

Authors:  Helio S Sader; Michael D Huband; Mariana Castanheira; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

Review 2.  Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.

Authors:  Jordan L Liscio; Monica V Mahoney; Elizabeth B Hirsch
Journal:  Int J Antimicrob Agents       Date:  2015-06-14       Impact factor: 5.283

3.  Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.

Authors:  Mariana Castanheira; Leonard R Duncan; Rodrigo E Mendes; Helio S Sader; Dee Shortridge
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

4.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.

Authors:  Lindsey M Weiner; Amy K Webb; Brandi Limbago; Margaret A Dudeck; Jean Patel; Alexander J Kallen; Jonathan R Edwards; Dawn M Sievert
Journal:  Infect Control Hosp Epidemiol       Date:  2016-08-30       Impact factor: 3.254

5.  Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.

Authors:  Deanna J Buehrle; Ryan K Shields; Liang Chen; Binghua Hao; Ellen G Press; Ammar Alkrouk; Brian A Potoski; Barry N Kreiswirth; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 6.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

7.  Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.

Authors:  M Berrazeg; K Jeannot; Véronique Yvette Ntsogo Enguéné; I Broutin; S Loeffert; D Fournier; P Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

8.  An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance.

Authors:  Scott T Micek; Richard G Wunderink; Marin H Kollef; Catherine Chen; Jordi Rello; Jean Chastre; Massimo Antonelli; Tobias Welte; Bernard Clair; Helmut Ostermann; Esther Calbo; Antoni Torres; Francesco Menichetti; Garrett E Schramm; Vandana Menon
Journal:  Crit Care       Date:  2015-05-06       Impact factor: 9.097
  8 in total
  11 in total

1.  Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents.

Authors:  Tomefa E Asempa; David P Nicolau; Joseph L Kuti
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

2.  Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa.

Authors:  Laurent Poirel; José-Manuel Ortiz De La Rosa; Nicolas Kieffer; Véronique Dubois; Aurélie Jayol; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 3.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

4.  In vitro potency of antipseudomonal β-lactams against blood and respiratory isolates of P. aeruginosa collected from US hospitals.

Authors:  Safa S Almarzoky Abuhussain; Christina A Sutherland; David P Nicolau
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

Review 5.  Emerging therapies against infections with Pseudomonas aeruginosa.

Authors:  Burkhard Tümmler
Journal:  F1000Res       Date:  2019-08-07

6.  In-Depth Genomic and Phenotypic Characterization of the Antarctic Psychrotolerant Strain Pseudomonas sp. MPC6 Reveals Unique Metabolic Features, Plasticity, and Biotechnological Potential.

Authors:  Matias Orellana-Saez; Nicolas Pacheco; José I Costa; Katterinne N Mendez; Matthieu J Miossec; Claudio Meneses; Eduardo Castro-Nallar; Andrés E Marcoleta; Ignacio Poblete-Castro
Journal:  Front Microbiol       Date:  2019-05-24       Impact factor: 5.640

Review 7.  A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections.

Authors:  Muhammad Waqas Saeed; Syed Wasif Gillani; Rana Kamran Mahmood; Prasanna Vippadapu; Mian Waqar Hussain; Hassaan Anwer Rathore
Journal:  Biomed Res Int       Date:  2022-08-08       Impact factor: 3.246

8.  Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents.

Authors:  Mariana Castanheira; Lalitagauri M Deshpande; Rodrigo E Mendes; Timothy B Doyle; Helio S Sader
Journal:  JAC Antimicrob Resist       Date:  2022-09-30

9.  Multicentre study of the in vitro activity of ceftolozane/tazobactam and other commonly used antibiotics against Pseudomonas aeruginosa isolates from patients in the UK.

Authors:  Adela Alvarez-Buylla; Mike Allen; Dan Betts; Sean Bennett; Irene Monahan; Tim Planche
Journal:  JAC Antimicrob Resist       Date:  2020-05-30

10.  First Study of Antimicrobial Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Against Pseudomonas aeruginosa Isolated from Patients with Urinary Tract Infection in Tehran, Iran.

Authors:  Mohammad Rahimzadeh; Mehri Habibi; Saeid Bouzari; Mohammad Reza Asadi Karam
Journal:  Infect Drug Resist       Date:  2020-02-17       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.